Literature DB >> 24976470

Resolution of left ventricular thrombus by rivaroxaban.

Miriam Padilla Pérez1, Daniel Salas Bravo, Juan Arsenio Garcelán Trigo, Eduardo Vazquez Ruiz de Castroviejo, Javier Torres Llergo, Cristóbal Lozano Cabezas, Juan Carlos Fernández Guerrero.   

Abstract

Intracardiac thrombus is a potentially life-threatening condition, with a high risk of embolic complications. Although vitamin K antagonists have been traditionally used for the treatment of intracardiac thrombus, they have relevant disadvantages that limit their use. Rivaroxaban is a once daily oral anticoagulant, currently indicated for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, and for the prevention and treatment of venous thromboembolism. We present the case of a 78-year-old man with nonvalvular atrial fibrillation, heart failure and creatinine clearance of 40 ml/min, anticoagulated with rivaroxaban 15 mg/day as the patient had very difficult access to hematologic controls. The transthoracic echocardiogram showed dilated left ventricle, severe left ventricular dysfunction and two images of thrombus, which disappeared after 4 weeks of treatment with rivaroxaban. To our knowledge, this is the first case reported regarding the resolution of left ventricular thrombosis with rivaroxaban.

Entities:  

Keywords:  atrial fibrillation; heart failure; intracardiac thrombus rivaroxaban; vitamin K antagonists

Mesh:

Substances:

Year:  2014        PMID: 24976470     DOI: 10.2217/fca.14.12

Source DB:  PubMed          Journal:  Future Cardiol        ISSN: 1479-6678


  11 in total

1.  Off label use of direct oral anticoagulants for left ventricular thrombus. Is it appropriate?

Authors:  George Degheim; Abeer Berry; Marcel Zughaib
Journal:  Am J Cardiovasc Dis       Date:  2017-11-01

2.  Oral factor Xa inhibitors for the treatment of left ventricular thrombus: a case series.

Authors:  Keaton S Smetana; Jessie Dunne; Kevin Parrott; George A Davis; Amy C Schmelzer Collier; Mary Covell; Susan Smyth
Journal:  J Thromb Thrombolysis       Date:  2017-11       Impact factor: 2.300

Review 3.  Non-vitamin K antagonist oral anticoagulants for the treatment of intracardiac thrombosis.

Authors:  Eiman Ghaffarpasand; Maneli D Tehrani; Jolanta Marszalek; Gerald Chi
Journal:  J Thromb Thrombolysis       Date:  2018-10       Impact factor: 2.300

Review 4.  Anticoagulation and stress-induced cardiomyopathy.

Authors:  Saagar K Sanghvi; David M Harris
Journal:  J Thromb Thrombolysis       Date:  2019-01       Impact factor: 2.300

Review 5.  Challenges in management of left ventricular thrombus.

Authors:  Fuad Habash; Srikanth Vallurupalli
Journal:  Ther Adv Cardiovasc Dis       Date:  2017-06-07

6.  Dabigatran Effect on Left Ventricular Thrombus in a Patient with Acute Ischemic Stroke.

Authors:  Kyuyoon Chung; Young Min Paek; Hye Jung Lee; Keun-Sik Hong
Journal:  J Stroke       Date:  2015-09-30       Impact factor: 6.967

7.  Resolution of left ventricular postinfarction thrombi in patients undergoing percutaneous coronary intervention using rivaroxaban in addition to dual antiplatelet therapy.

Authors:  Constantinos Andreas Makrides
Journal:  BMJ Case Rep       Date:  2016-10-26

8.  Rapid resolution of left ventricular thrombus with apixaban therapy.

Authors:  Abeer Berry; Daniel Brancheau; Marcel Zughaib
Journal:  SAGE Open Med Case Rep       Date:  2017-12-11

9.  Dabigatran Added to Dual Antiplatelet Therapy to Treat a Left Ventricular Thrombus in an 87 Year Old Patient With Myocardial Infarction and Very High Bleeding Risk.

Authors:  Maria Noflatscher; Nicolas Moes; Eva-Maria Gassner; Peter Marschang
Journal:  Front Pharmacol       Date:  2018-04-04       Impact factor: 5.810

10.  Resolution of left ventricular thrombus by edoxaban after failed treatment with warfarin overdose: A case report.

Authors:  Pei-Heng Kao; Ping-Yin Chou; Po-Chao Hsu; Tien-Chi Huang
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.